Orser Capital Boosts Johnson & Johnson Holdings

Hedge fund adds over $1 million in shares of pharmaceutical giant

Mar. 28, 2026 at 9:23am

Got story updates? Submit your updates here. ›

Orser Capital Management LLC, a financial services firm, has purchased a new position in shares of Johnson & Johnson (NYSE: JNJ) valued at approximately $1.08 million. The move comes as the healthcare company continues to see strong institutional investor interest.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a portfolio spanning pharmaceuticals, medical devices, and consumer products. Institutional investors closely monitor changes in ownership of the stock, as it is considered a bellwether for the broader healthcare sector.

The details

According to a recent SEC filing, Orser Capital Management purchased 5,217 shares of Johnson & Johnson stock in the fourth quarter. The purchase represents a new position for the firm, which previously did not hold any shares of the company. The $1.08 million investment comes as Johnson & Johnson stock has seen steady gains, rising over 13% in the past year.

  • Orser Capital Management purchased the shares in the fourth quarter of 2025.
  • Johnson & Johnson stock has risen over 13% in the past 12 months.

The players

Orser Capital Management LLC

A financial services firm that has purchased a new position in shares of Johnson & Johnson.

Johnson & Johnson

A multinational healthcare company that develops, manufactures, and markets a broad range of products across pharmaceuticals, medical devices, and consumer health.

Got photos? Submit your photos here. ›

What they’re saying

“Johnson & Johnson continues to be a highly sought-after investment given its diversified portfolio and strong market position.”

— Analyst

What’s next

Investors will continue to monitor Johnson & Johnson's financial performance and any changes in institutional ownership of the stock.

The takeaway

The purchase by Orser Capital Management underscores the ongoing appeal of Johnson & Johnson as a defensive healthcare investment, even as the broader market faces economic headwinds.